Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma

Archives of Ophthalmology

Volumn 125, Issue 12, 2007, Pages 1663-1667

  Hatef, Elham ^a   Roberts, Dianna ^a   McLaughlin, Peter ^a   Pro, Barbara ^a   Esmaeli, Bita ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; MESNA; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EYE EXAMINATION; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MEDICAL RECORD REVIEW; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULAR ADNEXAL LYMPHOMA; ORBIT TUMOR; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; T CELL LYMPHOMA; THORAX RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; CONJUNCTIVAL NEOPLASMS; DISEASE-FREE SURVIVAL; EYELID NEOPLASMS; FEMALE; GALLIUM RADIOISOTOPES; HUMANS; LYMPHOMA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; ORBITAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; RADIOGRAPHY, THORACIC; RADIOTHERAPY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 37149008523     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.125.12.1663     Document Type: Article

References (18)

1. Esmaeli B, Murray JL, Ahmadi MA, et al. Immunotherapy for low-grade non-Hodgkin secondary lymphoma of the orbit. Arch Ophthalmol. 2002;120(9):1225-1227.
2. Suh CO, Shim SJ, Lee SW, Yang WI, Lee SY, Hahn JS. Orbital marginal zone B-cell lymphoma of MALT: radiotherapy results and clinical behavior. Int J Radiat Oncol Biol Phys. 2006;65(1):228-233.
3. Galieni P, Polito E, Leccisotti A, et al. Localized orbital lymphoma. Haematologica. 1997;82(4):436-439.
4. Jenkins C, Rose GE, Bunce C, et al. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol. 2000;84(8):907-913.
5. Tanimoto K, Kaneko A, Suzuki S, et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol. 2006;17(1):135-140.
6. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21(22):4157-4164.
7. Charlotte F, Doghmi K, Cassoux N, et al. Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases. Virchows Arch. 2006;448(4):506-516.
8. Raderer M, Vorbeck F, Formanek M, et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer. 2000;83(4):454-457.
9. Cahill M, Barnes C, Moriarty P, Daly P, Kennedy S. Ocular adnexal lymphoma-comparison of MALT lymphoma with other histological types. Br J Ophthalmol. 1999;83(6):742-747.
10. Martinet S, Ozsahin M, Belkac'emi Y, et al. Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;55(4):892-898.
11. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013-7023.
12. McKelvie PA, McNab A, Francis IC, Fox R, O'Day J. Ocular adnexal lymphoproliferative disease: a series of 73 cases. Clin Experiment Ophthalmol. 2001;29(6):387-393.
13. Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys. 2003;57(5):1382-1391.
14. Rosado MF, Byrne GE Jr, Ding F, et al. Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood. 2006;107(2):467-472.
15. Yoon JS, Ma KT, Kim SJ, et al. Prognosis for patients in a Korean population with ocular adnexal lymphoproliferative lesions. Ophthal Plast Reconstr Surg. 2007;23(2):94-99.
16. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-2833.
17. Davies AJ. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I (131) tositumomab. Oncogene. 2007;26(25):3614-3628.
18. Sullivan TJ, Grimes D, Bunce I. Monoclonal antibody treatment of orbital lymphoma. Ophthal Plast Reconstr Surg. 2004;20(2):103-106.